TDO2 and prostate carcinoma: On the other hand, overexpressing TDO2 in LNCaP cells improved the resistance of cells to ADT (Fig. 2e; Supplementary Fig. S4b), indicating that TDO2 upregulation functioned to prevent prostate cancer cell death after ADT.